UK Markets closed
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • FTSE 250

    22,734.13
    +125.37 (+0.55%)
     
  • AIM

    1,249.65
    +3.03 (+0.24%)
     
  • GBP/EUR

    1.1648
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.4221%)
     
  • BTC-GBP

    25,487.10
    -747.50 (-2.85%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.36 (+0.04%)
     
  • CRUDE OIL

    70.78
    +0.49 (+0.70%)
     
  • GOLD FUTURES

    1,879.50
    -16.90 (-0.89%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     
  • HANG SENG

    28,842.13
    +103.25 (+0.36%)
     
  • DAX

    15,693.27
    +122.05 (+0.78%)
     
  • CAC 40

    6,600.66
    +54.17 (+0.83%)
     

Fosun Pharma unit to form tie-up with BioNTech for vaccine doses

·1-min read
The new manufacturing facility will be able to produce up to a billion shots of the vaccine a year, according to Fosun

A unit of a Chinese giant Shanghai Fosun Pharmaceutical has agreed a $200 million joint-venture with Germany's BioNTech to make coronavirus vaccines, according to a company filing.

Shanghai Fosun Pharmaceutical Industry Development will contribute up to $100 million in assets including cash and a manufacturing facility, capable of producing up to a billion jabs a year, according to the statement by the parent company on Sunday.

The announcement comes after the United States backed a plan for a waiver on Covid-19 patent protections, in a bid to get the drugs to poorer countries -- sending shares in Asia-listed vaccine makers tumbling last week.

Fosun said the joint venture firm for manufacturing and commercialising coronavirus vaccines will be owned 50 percent each by each company.

The 15-year joint venture would be incorporated in Shanghai.

BioNTech will contribute assets such as "licensing of the relevant manufacturing technology and know-how", the statement said.

bys/apj/dan